948 related articles for article (PubMed ID: 22951205)
1. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
Høgh AL
Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
[TBL] [Abstract][Full Text] [Related]
2. Age- and gender-related differences in the use of secondary medical prevention after primary vascular surgery: a nationwide follow-up study.
Høgh A; Lindholt JS; Nielsen H; Jensen LP; Johnsen SP
Eur J Vasc Endovasc Surg; 2012 Mar; 43(3):300-7. PubMed ID: 22244910
[TBL] [Abstract][Full Text] [Related]
3. Secondary medical prevention after primary vascular surgery between 1996 and 2006: a shift towards more evidence-based treatment.
Høgh A; Lindholt JS; Nielsen H; Jensen LP; Johnsen SP
Eur J Prev Cardiol; 2013 Oct; 20(5):763-70. PubMed ID: 22637739
[TBL] [Abstract][Full Text] [Related]
4. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
[TBL] [Abstract][Full Text] [Related]
5. Use of angiotensin-converting enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a nationwide propensity score matched follow-up study.
Høgh A; Lindholt JS; Nielsen H; Jensen LP; Johnsen SP
Vasc Endovascular Surg; 2012 Oct; 46(7):515-23. PubMed ID: 22843293
[TBL] [Abstract][Full Text] [Related]
6. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
7. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
Sigvant B; Wiberg-Hedman K; Bergqvist D; Rolandsson O; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
[TBL] [Abstract][Full Text] [Related]
8. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Naderi SH; Bestwick JP; Wald DS
Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
[TBL] [Abstract][Full Text] [Related]
9. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
Sigvant B; Henriksson M; Lundin F; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
[TBL] [Abstract][Full Text] [Related]
10. Re: Secondary medical prevention in patients with peripheral arterial disease.
Schouten O; Welten GM; Bax JJ; Poldermans D
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
[No Abstract] [Full Text] [Related]
11. Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries.
Hackam DG; Tan MK; Lin PJ; Mehta PG; Jaffer S; Kates M; Oh M; Grima EA; Langer A; Goodman SG; ;
J Vasc Surg; 2006 Oct; 44(4):776-81. PubMed ID: 16930931
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Blinc A; Poredos P
Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
[TBL] [Abstract][Full Text] [Related]
13. [Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice].
Philippe F; Cambou JP; Danchin N; Thomas D
Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S30-6. PubMed ID: 16411649
[TBL] [Abstract][Full Text] [Related]
14. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.
Subherwal S; Patel MR; Kober L; Peterson ED; Jones WS; Gislason GH; Berger J; Torp-Pedersen C; Fosbol EL
Circulation; 2012 Sep; 126(11):1345-54. PubMed ID: 22874581
[TBL] [Abstract][Full Text] [Related]
15. Use of evidence-based therapy for the prevention of cardiovascular events among older people.
Castelino RL; Chen TF; Guddattu V; Bajorek BV
Eval Health Prof; 2010 Sep; 33(3):276-301. PubMed ID: 20801973
[TBL] [Abstract][Full Text] [Related]
16. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
[TBL] [Abstract][Full Text] [Related]
17. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
[TBL] [Abstract][Full Text] [Related]
18. Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction.
Feringa HH; Bax JJ; Karagiannis SE; Noordzij P; van Domburg R; Klein J; Poldermans D
Arch Gerontol Geriatr; 2009; 48(1):116-20. PubMed ID: 18177954
[TBL] [Abstract][Full Text] [Related]
19. Atherosclerotic risk factor control in patients with peripheral arterial disease.
Rehring TF; Sandhoff BG; Stolcpart RS; Merenich JA; Hollis HW
J Vasc Surg; 2005 May; 41(5):816-22. PubMed ID: 15886666
[TBL] [Abstract][Full Text] [Related]
20. New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery.
Bauer SM; Cayne NS; Veith FJ
J Vasc Surg; 2010 Jan; 51(1):242-51. PubMed ID: 19954922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
